Why GT Biopharma’s B7-H3 TriKE could reshape immunotherapy for solid tumors

GT Biopharma’s GTB-5550 gets FDA clearance for a Phase 1 solid tumor trial. Find out how this NK cell engager could reshape B7-H3 cancer immunotherapy.

GT Biopharma’s GTB-5550 gets FDA clearance for a Phase 1 solid tumor trial. Find out how this NK cell engager could reshape B7-H3 cancer immunotherapy.